Tag: merger
-
GSK Acquires Advanced Vaccine Biotech in $3.3B Deal
Drug maker GSK is buying a biotechnology company developing vaccines for respiratory and infectious diseases that generate multiple immune responses.
-
Partnership Developing Faster, Sensitive Covid-19 Test
A collaboration between developers of protein analytics and test-strip diagnostics aims to create a quicker, more sensitive, easy-to-use Covid-19 detection test.
-
Digital Mental Therapy Company to Go Public in Merger
A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC.
-
Novo Nordisk Buys RNA Biotech in $3.3B Deal
Global drug maker Novo Nordisk is acquiring biotechnology company Dicerna Pharmaceuticals Inc. in an all-cash deal valued at $3.3 billion.
-
Synthetic Antibody Company Goes Public in $230M Merger
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger.
-
RNA Manufacturer Goes Public in $282M Merger
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition.
-
Protein Chemistry Biotech Acquired in $2B Deal
Drug maker Bayer is acquiring a company discovering new therapies with a technology that reveals complex protein targets considered difficult to address.
-
Sanofi Acquires mRNA Developer in $3.2B Deal
Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator.
-
Neuro Disease Start-Up Raises $73M in Early Funds
A new enterprise discovering treatments for neurodegenerative diseases is merging with another start-up and raising $73 million its first venture round.
-
Synthetic Bio Company Goes Public in $2.5B Merger
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition.